Covid19 Clinical Trial
— IMPACCTOfficial title:
Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic (IMPACCT COVID-19): a Prospective, Multicentre, Mixed-methods Cohort Study
NCT number | NCT04979897 |
Other study ID # | 2020-78 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 5, 2020 |
Est. completion date | February 2, 2022 |
Intensive care unit (ICU) survivors and their families frequently present mental, cognitive and physical impairments lasting years. The ongoing pandemic could affect the duration, variety, and severity of these impairments. Our aim is to determine the impact of the COVID-19 pandemic on the physical, mental, and cognitive health of survivors, the experience of their families and their treating healthcare professionals in the long-term. This is a prospective, multicentre, mixed-methods cohort study in seven Chilean ICUs. The perceptions of family members regarding the ICU stay and the later recovery will be explored 3 months after discharge. Health care professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews.
Status | Recruiting |
Enrollment | 450 |
Est. completion date | February 2, 2022 |
Est. primary completion date | November 2, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (=18 years old) - Mechanically ventilated for at least 48 hours Exclusion Criteria: - Unable to walk independently 2 weeks prior to ICU admission (with or without a gait aid) - S5q < 5 or CAM-ICU positive within 72 hours after ICU discharge - Patient who do not understand or speak Spanish - Patient unable to communicate verbally - Burn or severe trauma as admission diagnosis - Any neurological disorder (i.e. spinal cord injury, stroke and brain tumours) as admission diagnosis - Transferred to a non-participating study centre before ICU discharge assessment - Recent prolonged hospital stay (extended by more than 3 months) |
Country | Name | City | State |
---|---|---|---|
Chile | Hospital Regional Dr. Leonardo Guzmán de Antofagasta | Antofagasta | |
Chile | Hospital San Pablo de Coquimbo | Coquimbo | |
Chile | Clínica Alemana de Santiago | Santiago | |
Chile | Clínica BUPA | Santiago | |
Chile | Clínica INDISA | Santiago | |
Chile | Hospital del Salvador | Santiago | |
Chile | Hospital Metropolitano | Santiago |
Lead Sponsor | Collaborator |
---|---|
Universidad del Desarrollo | Clinica Alemana de Santiago, Clínica BUPA, Clínica INDISA, Hospital del Salvador, Hospital Metropolitano, Hospital Regional Dr. Leonardo Guzmán de Antofagasta, Hospital San Pablo de Coquimbo |
Chile,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Consent rate | Number of patients who agreed to participate divided by the number of patients who meet selection criteria | Every month during one year | |
Other | Cohort retention rate | Number of patients who can be contacted and evaluated | Every month during one year | |
Primary | World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) | The WHODAS 2.0 is a self-reported disability questionnaire based on the International Classification of Functioning, Disability, and Health (ICF). It includes 36 questions, organised under six domains (cognition, mobility, self-care, getting along, life activities and participation). Each question must be answered based on the perceived difficulty for performing activities using a 5-point scale (none, mild, moderate, severe and extreme) | 6 months after the ICU discharge | |
Secondary | Clinical Frailty Scale | The CFS evaluates specific domains including physical functioning, activities of daily living (ADL), instrumental ADL, assistance for personal care, comorbidities, and cognition to generate a frailty score using a 9-point scale ranging from 1 (very fit) to 9 (terminally ill). A score greater than 4 is considered fragile | Within 72 hours from ICU discharge | |
Secondary | Medical Research Council Sum Score (MRC-SS) | standardised examination of six muscle groups bilaterally (i.e. shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and dorsiflexion) | Within 72 hours from ICU discharge | |
Secondary | Functional Status Score for the Intensive Care Unit (FSS-ICU) | The FSS-ICU is a mobility instrument to score the level of physical assistance required when performing five functional activities: rolling, transfer from supine to sit, sitting at the edge of the bed, transfer from sitting to stand, and walking | Within 72 hours from ICU discharge | |
Secondary | Montreal Cognitive Assessment-Blind (MoCA blind) | The MoCA blind is a cognitive screening tool designed to detect cognitive dysfunction in five areas: memory, attention, language, abstraction and orientation. It requires 5 minutes to be completed | Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | The HADS is an interviewer or self-administered questionnaire designed to identify anxiety and depressive symptoms in a wide variety of in-hospital patients, which requires between 2 and 5 minutes to be completed | Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge | |
Secondary | Impact of Events Scale-Revised (IES-R) | The IES-R is an interviewer or self-administered questionnaire designed to measure the subjective distress caused by traumatic events that has been validated for critical illness survivors | Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge | |
Secondary | European Quality of Life Health Questionnaire (EQ-5D-3L) | The EQ-5D-3L is an interviewer or self-administered questionnaire of health status or health-related quality of life, including five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and global health state | 3 months, and 6 months after the ICU discharge | |
Secondary | Employment status | The employment status will be evaluated using tailored questions regarding current occupation, working hours, and any changes to their employment situation as it has been used elsewhere | Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge | |
Secondary | Survival | Number of patients who survived | Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge | |
Secondary | Actigraphy | To measure sedentary behaviour and physical activity | 6 months after the ICU discharge | |
Secondary | Global Physical Activity Questionnaire (GPAQ) | To measure sedentary behaviour and physical activity | 6 months after the ICU discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |